Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody

• Published in: BMJ open Vol. 11; no. 3; p. e040465
• Main Authors: Kamiya, Hiroyuki, Panlaqui, Ogee Mer
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 31.03.2021; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Antibodies; Bias; Classification; Clinical medicine; interstitial lung disease; Lung diseases; Meta-analysis; Mortality; Patients; Peptides; Respiratory Medicine; Rheumatoid arthritis; Rheumatology; Statistical analysis; Systematic review; thoracic medicine; rheumatology; interstitial lung disease; thoracic medicine

ObjectiveTo clarify the risk of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) related to anti-cyclic citrullinated peptide (CCP) antibody.Eligibility criteriaPatients with RA with and without ILD were eligible. The primary outcome was the prevalence or incidence of ILD. Primary...